focus -WSS

focus

author：comprehensive 2025-10-02 18:47:47 - browse：96363

A sign of Lilly on the top of its biotechnology center — coverage from STAT — Adobe

Eli Lilly reported Thursday that its experimental weekly insulin worked as well as daily basal insulin products in two late-stage studies, paving the way for the drug to compete with a similar weekly insulin developed by Novo Nordisk.

In a 52-week trial of type 2 diabetes patients using insulin for the first time, those on the weekly insulin, called efsitora alfa, had a 1.34% reduction in blood sugar levels, while people on the comparator daily insulin degludec, sold as Tresiba by Novo, had a 1.26% lowering. That resulted in patients having blood sugar levels, known as A1C readings, of 6.87% and 6.95%, respectively.

In a separate 26-week trial of type 2 patients who have been using insulin, those on efsitora and the comparator daily insulin glargine, sold by Lilly as Basaglar and Sanofi as Lantus, both saw A1C reductions of 1.07%, resulting in blood sugar levels of 7.12% and 7.11%, respectively.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Diabetes management: Digital health tools fall short, study says

hotspot

WSS

CRISPR technology availability, affordability needs to be expanded

With Wegovy coverage, Medicare patients may face high costs

Kaiser Permanente unions announce official strike date

Mindstrong's demise and the future of mental health care

Data show record exodus of life scientists from academia

Cigna to pay $172 million to settle Medicare Advantage fraud probe

knowledge

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

Sports medicine is finally prioritizing gender equality

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

Anesthesiologist group: stop taking Ozempic before surgery

Mindstrong's demise and the future of mental health care

Anesthesiologist group: stop taking Ozempic before surgery

Pregnancy ages women, but effects reverse after delivery

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Cancer, immunology, HIV research ensnared in fetal tissue politics

Alkermes shareholders re

Listen: Who gets the credit for GLP

entertainment

Medicare Advantage insurers pressure Biden for bigger payments

CRISPR technology availability, affordability needs to be expanded

Shingles, which affected Dianne Feinstein, is on the rise

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

Why do women spend more than men on medical expenses?

Mindstrong's demise and the future of mental health care

focus

hotspot

hotspot

knowledge